Total Funding
2
Total FundingVenture - Series Unknown raised
Growth Score
pts
Heat Score
-3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
Affymax is a biopharmaceutical company.
Arlene Morris: CEO- Paul Cleveland: Executive Vice President and Chief Financial OfficerPast Role: Celladon, President and Chief Executive Officer
About the Company
Affymax is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. The company's first product candidate, peginesatide (formerly known as Hematide™), has been investigated in Phase 3 trials for the potential treatment of anemia associated with chronic kidney
disease (CKD). A New Drug Application (NDA) for peginesatide for the treatment of anemia associated with CKD in adult patients on dialysis is currently being reviewed by the U.S. Food and Drug Administration (FDA).
